Repare Therapeutics RPTX 深 沪
交易中 08-24 10:20:52 美东时间
2.65
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 2.65
- 总市值 1.14亿
- 52周最高 2.66
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.89
- 委 比 0.00%
- 总股本 4310.84万
- 历史最高 46.44
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.89
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Pyxis Oncology reported financial results for Q1 2026 and highlighted advancements in its MICVO clinical development program. The company expects to share updated monotherapy data for 2L+ recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated at or below a dose cap in mid-2026, and combination data with pembrolizumab in 1L R/M HNSCC patients in late 2026. They also presented preclinical data supporting MICVO's pot...
05-14 11:00
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Pyxis Oncology, Inc. reported updates on its lead candidate MICVO, including completion of target enrollment in a Phase 1 monotherapy study for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the first quarter of 2026. The company also announced updated data expected in mid-2026, which will include patients treated with modified weight-based dosing. Additionally, Pyxis Oncology shared financial results for 2025, includin...
03-23 11:00
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
Pyxis Oncology Inc. announced that Thomas Civik has been appointed Interim Chief Executive Officer, succeeding Lara S. Sullivan, M.D., as President, CEO, and CMO. Civik, a board member with extensive biotech experience, will lead the company through its strategic and clinical goals. Lara Sullivan expressed gratitude for her six-year tenure leading the advancement of the lead candidate, MICVO. The company remains focused on advancing MICVO in Phas...
02-03 11:45
Repare Therapeutics Receive Shareholders Approval Of Its Acquisition By XenoTherapeutics
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued
01-17 06:01
美股牛股 | 奥麦罗制药涨超75%，YARTEMLEA药物获得FDA批准；德纳维制药涨超38%
奥麦罗制药涨超75%，YARTEMLEA药物获得FDA批准；德纳维制药涨超38%，获法国制药巨头22亿美元收购；Sidus Space涨超33%，获美国导弹防御局合同>>
2025-12-26 18:41
美股异动 | 与吉利德科学(GILD.US)达成出售实验性抗癌资产协议 Repare Therapeutics(RPTX.US)盘前一度大涨约20%
该公司已与吉利德科学达成资产购买协议，收购其实验性抗癌疗法RP-3467，交易总价值最高可达3000万美元
2025-12-24 22:19
Market-Moving News for December 24th
PATH: 8% | UiPath To Replace Synovus Financial In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Friday, January 2; Versant Media Group To Replace Brandywine Realty Trust In The S&P Smallcap
2025-12-24 20:20
Repare Therapeutics Sells Cancer Drug Asset To Gilead For Up To $30M
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's
2025-12-24 20:19
